Investor Presentation
Mangalam Drugs & Organics Ltd has informed BSE regarding "Investor Presentation - August 2016".03-08-2016
03-08-2016
Standalone Financial Results, Limited Review Report for June 30, 2016
Mangalam Drugs & Organics Ltd has informed BSE about : 1. Standalone Financial Results for the period ended June 30, 20162. Standalone Limited Review for the period ended June 30, 201601-08-2016
Board Meeting Intimation for Results & Closure of Trading Window
Mangalam Drugs & Organics Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on Monday, August 01, 2016 at the registered office of the Company at Mumbai, inter-alia to consider and approve the following:- To approve, consider and take on record the Unaudited Financial Results of the company for the quarter ended June 30, 2016....23-07-2016
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended June 30, 2016
Mangalam Drugs & Organics Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended June 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.21-07-2016
Shareholding for the Period Ended June 30, 2016
Mangalam Drugs & Organics Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2016. For more details, kindly Click here11-07-2016
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Shri JB Pharma LLP has submitted the disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 201110-06-2016
Outcome of Board Meeting
Mangalam Drugs & Organics Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 10, 2016, inter alia, has transacted the following business:- Approved the allotment of balance 14,50,000 Equity Shares of Rs. 10/- each at a premium of Rs. 55/- per share pursuant to exercise of right for conversion of remaining 14,50,000 warrants into equity shares to the promoter group on preferential basis, upon the receipt of balance consideration amount on it.10-06-2016
Corrigendum to Financial Results for March 31, 2016
With the reference to the earlier Announcement dated May 16, 2016, regarding Financial Results for March 31, 2016, Mangalam Drugs & Organics Ltd has informed BSE that there is a minor typographical error(s) which was caused inadvertently due to error in excel sheet w.r.t. Statement of Assets and Liabilities (Standalone). The figures of the Statement of Assets and Liabilities were mistyped and needs correction in year ended 31st March, 2016 results....03-06-2016
Board Meeting postponed on June 10, 2016
With reference to the earlier letter dated May 26, 2016 regarding the meeting of Board of Directors of the Company which was scheduled on June 06, 2016, inter alia, to consider and approve the allotment of 14,50,000 Equity Shares on conversion of remaining 14,50,000 Share Warrants which were allotted on preferential basis to Shri JB Pharma LLP, (Promoter or Proposed Allottee) on September 28, 2015 and the issue of which was approved by the shareholders...02-06-2016
Board Meeting on June 06, 2016
Mangalam Drugs & Organics Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on June 06, 2016, inter alia, to consider and approve the allotment of 14,50,000 Equity Shares on conversion of remaining 14,50,000 Share Warrants which were allotted on preferential basis to Shri JB Pharma LLP, (Promoter' or Proposed Allottee) on September 28, 2015 and the issue of which was approved by the shareholders at 42nd...26-05-2016